Alethio Therapeutics Unveils ATX-011, First-in-Class Mutation-Agnostic Antibody for Essential Thrombocythemia Treatment
核心洞察
Alethio Therapeutics (搜索) announced ATX-011 (搜索), a first-in-class, mutation-agnostic antibody targeting the $2 billion Essential Thrombocythemia (搜索) market with potential to replace 50-year-old standard of care hydroxyurea.
The therapy demonstrated rapid platelet normalization within days in non-human primate models with zero myelosuppression and no safety signals, addressing limitations of current treatments.
The company appointed Steve R. Coats, PhD, as Chief Development Officer to advance ATX-011 (搜索) toward IND submission in Q1 2027 and clinical proof-of-concept data by H1 2028.
Alethio Therapeutics (搜索) has unveiled ATX-011 (搜索), a breakthrough first-in-class, mutation-agnostic monoclonal antibody designed to transform treatment for Essential Thrombocythemia (搜索) (ET), a chronic blood disorder affecting over 140,000 patients in the United States. The Oxford-based biopharmaceutical company announced the development alongside the appointment of veteran biologics leader Steve R. Coats, PhD, as Chief Development Officer to accelerate the program toward clinical trials.
Addressing Critical Limitations of Current Standard of Care
ATX-011 (搜索) is engineered to replace hydroxyurea, a 50-year-old chemotherapeutic that remains the most widely used treatment for ET despite significant limitations. Current therapy typically requires months to achieve platelet control, which most patients fail to reach, while carrying a 13% skin cancer risk and causing broad myelosuppression. Between 40-50% of hydroxyurea patients suffer resistance, intolerance, or chronic toxicity, with no reduction in the risk of transformation to more aggressive disease forms.
"Essential Thrombocythemia (搜索) has been inadequately treated for half a century by a toxic and outdated standard of care," said Rohit Batta, Chief Executive Officer of Alethio Therapeutics (搜索). "ATX-011 (搜索) was engineered to change that trajectory. Our mutation-agnostic approach means no patient is left behind, and our pre-clinical non-human primate data showing rapid platelet-lowering and an exceptional safety profile give us confidence that we can redefine what is possible in MPN care."
Promising Preclinical Data and Mechanism of Action
Through Alethio's proprietary ARTEMIS target-discovery and development engine, the company identified a surface target that enables selective removal of platelets and the mutant stem/progenitor cells that drive excess platelet production, independent of the patient's driver mutation. The target was orthogonally validated using samples from more than 80 myeloproliferative neoplasm (MPN) patients.
Non-human primate studies demonstrated ATX-011 (搜索)'s ability to deliver platelet normalization within days, showing zero myelosuppression and no safety signals—a clean profile that contrasts sharply with hydroxyurea's toxicity profile. The therapy's mutation-agnostic design positions it to serve the majority of the ET population, unlike emerging precision approaches targeting mutant CALR (搜索) that address only a narrow subset of patients.
Experienced Leadership to Drive Clinical Development
Steve R. Coats brings over 30 years of biopharmaceutical R&D leadership experience and deep expertise in advancing monoclonal antibody and antibody-drug conjugate (ADC) therapies from discovery through clinical development. Most recently serving as CDO at ImmunOs Therapeutics (搜索), Coats previously spent 15 years at AstraZeneca/MedImmune, where he led global cross-functional teams delivering multiple novel antibodies and ADCs through IND/CTA submissions and into Phase 2 clinical trials.
At AstraZeneca, Coats advanced five ADC programs into clinical development and played a key role in the landmark ADC licensing transaction with Daiichi Sankyo, which included a $1.3 billion upfront payment and up to $7 billion in total potential value.
"I joined Alethio because ATX-011 (搜索) stands out as one of the most compelling pre-clinical programs in the ET field," commented Coats. "Its ability to act rapidly, across all mutational backgrounds, with a clean safety profile is highly differentiated in a space dominated by an aging chemotherapeutic and narrow genetic sub-segment approaches."
Clinical Timeline and Market Opportunity
Alethio is targeting Q1 2027 for IND submission and H1 2028 for clinical proof-of-concept data. The company is advancing through Series A fundraising to support the accelerated development timeline.
Essential Thrombocythemia (搜索) represents a significant commercial opportunity within the broader $2 billion market, characterized by high platelet counts that create thrombosis risk, disease progression, and treatment-related toxicities driving significant morbidity. The chronic blood disorder remains largely underserved despite its substantial patient population.
ATX-011 (搜索) represents one of several medicines in Alethio's growing pipeline, including next-generation ADCs, purpose-built to address unmet needs across the full disease spectrum of myeloproliferative neoplasms (搜索). The company's ARTEMIS discovery platform integrates access to leading MPN biobanks, single-cell sequencing, organoids, and bioinformatics to de-risk first-in-human trials and identify new mutant drivers.